InvestorsHub Logo
Followers 37
Posts 6884
Boards Moderated 1
Alias Born 09/06/2014

Re: myjo post# 14907

Friday, 08/28/2020 9:12:11 AM

Friday, August 28, 2020 9:12:11 AM

Post# of 15618
I can answer those.

Is this incompetent CEO “ever” going to publish S-1?

This CEO is not incompetent. Far from it. He brought GuidedThera up from the ashes by clearing out the toxic debt and UPLISTING and getting the FDA trial started again. Amazing, IMO. Never seen anything like this in the pinksheets before.

Nobody here knows whether the company (not the CEO mind you, the COMPANY) will file that S-1. My educated guess is yes, they will, because they need to do that to pay for the clinical trial, and the accomplishments in the past year point towards this company being serious about getting FDA clearance/approval.

What’s status of SMI’s clinical trials? Weren’t they supposed to start clinical trials in summer? What’s status of SMI’s application for CFDA approval?

Forget about SMI. They have accomplished nothing and they WILL accomplish nothing. Who knows whether GuidedThera knew this all along or whether they actually believed SMI's BS in 2017-2019 but if you read my posts I have been saying for the past three years that SMI is China Hype and SMI will never get CFDA approval.

If you read the last couple of financial filings, you will learn that SMI has done nothing. After three years of SMI promises, they have done nothing.

CFDA approval is just as difficult if not MORE difficult to get that FDA approval. More important: SMI seems to be saying that the CFDA will classify the LuViva Scan as a Class II device, and that is nonsense, IMO. The US FDA is classifying it as Class III so of course the CFDA will too.

So in summary:

* Yes this company will file that S-1.
* SMI has done nothing, is doing nothing, and will do nothing.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GTHP News